Key Financials Snapshot

TTM · Consolidated · ₹ in Cr
Market Cap
₹32 Cr.
Stock P/E
10.6
P/B
0.6
Current Price
₹63.6
Book Value
₹ 108.6
Face Value
10
52W High
₹76.9
52W Low
₹ 45.3
Dividend Yield
0%

GKB Ophthalmics Overview

Business

GKB Ophthalmics Ltd. is an Indian company primarily engaged in the manufacturing and supply of ophthalmic lenses, specifically spectacle lenses. The company produces a comprehensive range of finished and semi-finished lenses made from various materials (e.g., CR-39, polycarbonate) and designs (single vision, bifocal, progressive). They also offer specialized coatings such as anti-reflective, anti-scratch, UV protection, and blue-cut. GKB Ophthalmics operates predominantly on a business-to-business (B2B) model, supplying its products to opticians, distributors, and retail chains across India and to some international markets. Their revenue is generated through the sale of these manufactured lenses.

Revenue Mix

GKB Ophthalmics' core business revolves around ophthalmic lenses. While specific revenue contribution percentages for different lens types are not publicly detailed, their product portfolio broadly covers:

Single Vision Lenses: Standard lenses for a single prescription.

Bifocal & Progressive Lenses: Lenses offering multiple vision zones.

Specialized Lenses: Including photochromic (light-adaptive) and polarized lenses.

Coated Lenses: Lenses with various functional coatings (e.g., Multi Anti-Reflective, Hard Multicoat, Blue Cut, UV Protection).

Their business is predominantly domestic (India), with a smaller portion attributed to exports.

Industry

GKB Ophthalmics operates within the highly competitive Indian ophthalmic lens market, which is part of the broader medical equipment and supplies sector. The industry is characterized by the presence of large global players (e.g., EssilorLuxottica, Zeiss, Hoya) alongside several domestic manufacturers and importers. GKB Ophthalmics holds a significant position as one of the leading Indian manufacturers of spectacle lenses. They differentiate themselves through a wide product range, focus on quality, and an established pan-India distribution network catering to a vast number of opticians. They compete primarily on product innovation, pricing, and distribution reach.

MOAT

GKB Ophthalmics possesses several competitive advantages, though these may not be considered strong, impenetrable moats:

Established Manufacturing & Scale: As one of India's larger domestic lens manufacturers, they benefit from economies of scale in production compared to smaller players.

Extensive Distribution Network: A well-developed pan-India distribution network allows them deep market penetration and reach to a wide base of opticians.

Brand Recognition (B2B): Within the Indian optical trade, GKB has an established brand reputation for reliability and product range.

Product Portfolio: A comprehensive range of lenses across various materials, designs, and coatings allows them to cater to diverse customer needs.

Cost Efficiency: Being a domestic manufacturer can provide cost advantages in certain segments compared to importing finished lenses.

Growth Drivers

Key factors that can drive GKB Ophthalmics' growth over the next 3-5 years include:

Rising Eye Care Awareness: Increasing awareness about eye health and the importance of regular eye check-ups among the Indian population.

Growing Disposable Incomes: Higher disposable incomes allow consumers to invest in better quality and specialized lenses.

Aging Population: An increasing elderly population in India will naturally drive demand for vision correction solutions.

Digital Lifestyle: Prolonged screen time among all age groups contributes to an increase in vision problems, driving demand for protective and corrective lenses (e.g., blue-cut lenses).

Penetration into Tier 2/3 Cities: Expansion into underserved semi-urban and rural markets offers significant growth potential.

Product Innovation: Introduction of new lens technologies, materials, and coatings to meet evolving consumer demands and competition.

Risks

GKB Ophthalmics faces several business risks:

Intense Competition & Pricing Pressure: The presence of large multinational corporations and numerous domestic players leads to significant pricing pressure and can erode margins.

Raw Material Price Volatility: Reliance on imported raw materials (e.g., monomers) exposes the company to fluctuations in global commodity prices and foreign exchange rates.

Technological Obsolescence: Rapid advancements in lens technology and manufacturing processes could render existing products or manufacturing techniques less competitive.

Economic Slowdown: As spectacle lenses can be considered a discretionary purchase, an economic downturn could impact consumer spending and demand for higher-value lenses.

Regulatory Changes: Changes in import duties, taxes, or quality standards for medical devices could impact operations and profitability.

Dependency on B2B Channel: Heavy reliance on opticians and distributors means that strong relationships and efficient channel management are critical; any disruption could impact sales.

Management & Ownership

GKB Ophthalmics Ltd. is promoted by the GKB family, who have a long-standing presence in the Indian ophthalmic industry. The company is primarily promoter-managed, with the family holding a significant stake in the company. This indicates a strong alignment of interests between the management and shareholders. Further details on specific management quality would require a deeper dive into their corporate governance, past performance, and strategic decisions. As of public records, the promoter holding is substantial, reflecting a closely held nature of the business.

Outlook

GKB Ophthalmics is positioned in a growing market driven by demographic trends and increasing health awareness in India. The company's established manufacturing base and extensive distribution network provide a solid foundation for capitalizing on this growth.

The bull case hinges on the increasing demand for eye care products in India due to factors like an aging population, rising disposable incomes, and widespread digital screen usage. GKB's ability to innovate its product portfolio, expand its reach into underserved markets, and maintain cost efficiencies could drive sustainable growth.

Conversely, the bear case points to intense competition from global giants and domestic players, which can lead to pricing pressures and margin erosion. The company's exposure to raw material price volatility and potential technological disruption in the ophthalmic lens market also pose significant challenges. Sustained success will depend on its ability to navigate these competitive and operational headwinds effectively while leveraging its domestic market strengths.

GKB Ophthalmics Share Price

Live · BSE / NSE · Inception: 1981
₹ | |
Volume
Price

Key Financials — Profit & Loss

₹ in Cr · Consolidated · annual

GKB Ophthalmics Quarterly Results

#(Fig in Cr.) Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Net Sales 22 26 26 26 31 32 30 57 30 33
Other Income 0 0 0 0 0 0 0 1 1 1
Total Income 22 26 26 26 31 33 31 58 31 34
Total Expenditure 22 25 26 27 34 31 27 55 27 30
Operating Profit 1 1 0 -0 -3 1 3 2 4 3
Interest 1 1 1 1 1 1 1 1 1 1
Depreciation 1 1 1 1 1 1 1 1 1 1
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 -1 0
Profit Before Tax -1 0 -1 -2 -4 -1 2 1 1 2
Provision for Tax 0 0 0 0 0 0 0 -0 -0 0
Profit After Tax -1 -0 -1 -2 -4 -1 2 1 1 2
Adjustments 0 -0 -0 -0 1 -0 -0 -0 -1 -1
Profit After Adjustments -1 -0 -1 -2 -4 -1 2 0 0 1
Adjusted Earnings Per Share -1.8 -0.5 -2.4 -4 -7 -2 3.2 0.9 0.4 2

GKB Ophthalmics Profit & Loss

#(Fig in Cr.) Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Net Sales 44 74 77 57 59 57 71 75 88 109 149 150
Other Income 2 1 0 2 0 2 1 1 2 1 2 3
Total Income 46 75 78 59 59 59 72 76 90 110 151 154
Total Expenditure 46 72 76 56 56 55 66 72 88 112 140 139
Operating Profit 0 3 2 3 3 4 6 5 2 -1 11 12
Interest 2 1 1 1 1 2 1 2 2 2 3 4
Depreciation 1 1 2 4 4 3 3 3 3 3 3 4
Exceptional Income / Expenses 11 3 0 0 0 -1 0 0 0 0 -2 -1
Profit Before Tax 8 3 -1 -2 -2 -1 2 0 -3 -7 3 6
Provision for Tax 4 0 -0 -0 0 -0 0 0 0 0 0 0
Profit After Tax 4 3 -1 -1 -2 -1 2 0 -3 -7 3 6
Adjustments 0 0 0 0 1 -0 -1 -0 0 0 -2 -2
Profit After Adjustments 4 3 -1 -1 -2 -1 1 -0 -3 -7 1 3
Adjusted Earnings Per Share 9.5 6.2 -2.3 -2.4 -3.6 -1.8 2.5 -0.3 -5.6 -14 2.4 6.5

GKB Ophthalmics Balance Sheet

#(Fig in Cr.) Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Shareholder's Funds 45 47 45 55 59 63 63 63 60 52 53
Minority's Interest 0 0 0 0 0 4 4 5 4 4 2
Borrowings 0 0 0 0 0 1 2 1 1 3 2
Other Non-Current Liabilities 2 2 2 5 5 5 6 6 7 7 8
Total Current Liabilities 23 37 36 37 41 38 39 41 46 62 71
Total Liabilities 69 86 83 97 106 111 114 116 118 129 136
Fixed Assets 13 18 18 26 26 24 23 19 18 17 15
Other Non-Current Assets 5 2 1 7 7 13 16 13 13 13 13
Total Current Assets 51 66 64 64 73 74 76 84 87 99 108
Total Assets 69 86 83 97 106 111 114 116 118 129 136

GKB Ophthalmics Cash Flow

#(Fig in Cr.) Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Opening Cash & Cash Equivalents 3 3 2 2 9 13 6 6 2 3 3
Cash Flow from Operating Activities -11 -3 -3 4 3 7 5 -3 4 -3 -4
Cash Flow from Investing Activities 15 4 1 -10 -4 -17 -4 1 -2 3 9
Cash Flow from Financing Activities -3 -1 1 13 4 3 -2 -2 -2 1 -6
Net Cash Inflow / Outflow 0 -1 0 7 4 -7 -0 -4 1 -0 -0
Closing Cash & Cash Equivalent 3 2 2 9 13 6 6 2 3 3 3

GKB Ophthalmics Ratios

# Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Earnings Per Share (Rs) 9.51 6.23 -2.34 -2.38 -3.65 -1.8 2.53 -0.33 -5.58 -13.98 2.42
CEPS(Rs) 13.1 9.68 1.75 4.99 2.32 4.75 9.15 5.84 -0.17 -7.92 12.43
DPS(Rs) 0 0 0 0 0 0 0 0 0 0 0
Book NAV/Share(Rs) 107.89 112.64 108.2 111.84 117.55 124.3 125.18 124.38 118.58 103.24 104.82
Core EBITDA Margin(%) -3.82 2.39 1.72 2 3.65 3.37 6.83 4.88 0.66 -2.55 5.78
EBIT Margin(%) 20.91 5.54 0.18 -0.37 -1.69 1.94 4.83 2.4 -0.99 -4 3.88
Pre Tax Margin(%) 17.33 3.85 -1.46 -2.97 -4.19 -1.63 2.74 0.18 -3.15 -6.17 2.08
PAT Margin (%) 8.67 3.38 -1.25 -2.14 -4.19 -1.32 2.74 0.15 -3.38 -6.5 2.03
Cash Profit Margin (%) 11.93 5.26 0.93 4.05 2 4.21 6.5 3.9 -0.09 -3.66 4.2
ROA(%) 5.48 3.34 -1.15 -1.36 -2.41 -0.69 1.73 0.1 -2.55 -5.72 2.28
ROE(%) 9.32 5.65 -2.12 -2.52 -4.41 -1.23 3.09 0.18 -4.87 -12.66 5.77
ROCE(%) 18.94 7.99 0.25 -0.34 -1.38 1.48 4.58 2.44 -1.2 -6.32 8.82
Receivable days 142.03 99.83 122.19 162.83 151.07 142.44 100.29 114.24 116.09 90.24 86.14
Inventory Days 169.82 124.36 147.17 190.76 181.31 211.22 188.1 184.84 162.86 151.37 128.56
Payable days 192.73 126.99 165.17 231.94 221.09 234.2 200.8 190.02 173.79 179.85 165.5
PER(x) 6.94 21.4 0 0 0 0 36.39 0 0 0 21.72
Price/Book(x) 0.61 1.18 1.07 0.83 0.37 0.66 0.73 0.87 0.74 0.58 0.5
Dividend Yield(%) 0 0 0 0 0 0 0 0 0 0 0
EV/Net Sales(x) 0.7 0.81 0.72 0.82 0.39 0.63 0.59 0.68 0.43 0.29 0.22
EV/Core EBITDA(x) 626.24 19.06 30.3 14.15 8.74 8.29 6.95 11.17 18.04 -21.42 3.06
Net Sales Growth(%) 24.38 69.3 4.5 -26.17 2.4 -2.83 24.72 6.4 16.93 23.49 36.77
EBIT Growth(%) 2193.92 -55.59 -96.77 -255.89 -362.64 211.85 210.17 -47.08 -148.14 -399.13 232.67
PAT Growth(%) 400.08 -34.53 -137.52 -25.86 -100.59 69.46 359.73 -94.02 -2664.14 -137.39 142.76
EPS Growth(%) 0 -34.53 -137.52 -1.8 -53.4 50.67 240.42 -113.14 -1578.92 -150.66 117.3
Debt/Equity(x) 0.16 0.15 0.22 0.27 0.26 0.19 0.19 0.18 0.19 0.28 0.22
Current Ratio(x) 2.25 1.8 1.75 1.72 1.76 1.94 1.95 2.03 1.89 1.59 1.52
Quick Ratio(x) 1.32 0.96 0.87 0.97 1.02 1.01 0.98 1.09 1.03 0.79 0.75
Interest Cover(x) 5.84 3.28 0.11 -0.14 -0.67 0.54 2.32 1.08 -0.46 -1.84 2.16
Total Debt/Mcap(x) 0.26 0.13 0.21 0.33 0.7 0.29 0.25 0.21 0.26 0.48 0.44

Growth Rates

Compounded annual
# 1 Year 3 Year 5 Year 10 Year
Sales CAGR +37% +26% +21% +13%
Operating Profit CAGR — +30% +22% —
PAT CAGR — — — -3%
Share Price CAGR -1% -14% -6% -7%
ROE Average +6% -4% -2% 0%
ROCE Average +9% 0% +2% +3%

GKB Ophthalmics Shareholding Pattern

Latest · Sep 2026
100% held
Promoters 51.15 %
FII 1.79 %
DII (MF + Insurance) 0 %
Public (retail) 47.07 %
# Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Promoter 50.9550.9550.9850.9951.0651.0651.1351.1351.1551.15
FII 1.791.791.791.791.791.791.791.791.791.79
DII 0000000000
Public 47.2747.2747.2347.2347.1647.1647.0947.0947.0747.07
Others 0000000000
Total 100100100100100100100100100100

GKB Ophthalmics Peer Comparison

Medical Equipment/Supplies/Accessories Edit Columns

GKB Ophthalmics Quarterly Price

10-year quarterly close · BSE
Show Value Show %

News & Updates

See more…

GKB Ophthalmics Pros & Cons

Pros

  • Stock is trading at 0.6 times its book value
  • Debtor days have improved from 179.85 to 165.5days.
  • Company has reduced debt.
  • Company is almost debt free.

Cons

  • Company has a low return on equity of -4% over the last 3 years.
Want to Start Investing in Top Unlisted Stocks?

Our experts help you choose the right stocks based on performance, risk, and growth potential.

whatsapp